🥤 Hemp Industry vs DC: Shutdown Deal, THC Ban, One-Year Clock

Built by a former cannabis regulator, Policy, Decoded helps operators see the policy terrain before it shifts beneath their feet.

Congress ended a forty day shutdown by turning hemp into the bargaining chip, and the bill that turned the lights back on in Washington also lit a fuse under a thirty billion dollar market. The next year will not feel like a grace period so much as a live negotiation, with retailers, governors, and regulators deciding in real time whether hemp drinks and CBD stay on shelves, move into cannabis channels, or vanish one awkward checkout conversation at a time. We recorded an emergency episode of The Hybrid with Pam Epstein to walk through how Congress got here, what the shutdown deal actually does, and where the industry needs to go next.

This edition is supported by AltIndex and The Marketing Millennials, and we are proud to offer 20% off tickets to the IgniteIt Cannabis Capital and Policy Summit in Washington, D.C. on November 17th with code POLICYDECODED20.

🥤 Hemp war?
🌾 What do the states do now?
⚖️ Time to get to work…

You can catch more flies with honey…

📌 What Happened: Politico’s Nightly newsletter frames the shutdown ending spending bill as the opening shot in a war over the $30 billion hemp industry. The legislation that reopened the federal government included language championed by Mitch McConnell that restricts intoxicating hemp products which flourished after the 2018 Farm Bill by exploiting the focus on delta-9 THC percentage. McConnell claims the provision simply preserves a legitimate hemp sector while shutting down dangerous, untested drugs sold to kids in gas stations and bodegas. Hemp operators argue the language is broad enough to wipe out non-intoxicating CBD and much of the existing supply chain, not just outlier synthetics. Advocates like Jim Higdon of Cornbread Hemp say competing industries, especially alcohol, pushed for a kill shot rather than age limits, testing requirements, and other guardrails that would have separated serious operators from opportunists. Rand Paul’s amendment to strip the hemp language failed in the Senate and the bill builds in a one year implementation period, which becomes the new timeline for an industry wide fight over whether Congress will adjust or double down on this definition.

💡 Why It Matters: Congress is now trying to stuff a nationwide THC and CBD market back into a statute that never anticipated aggressive chemistry, online sales, and prohibition state demand. Hemp products fill cannabis gaps in places like Texas and Tennessee where licensed marijuana channels do not exist, and the federal move lands on real consumer behavior instead of only fringe gas station gimmicks. The political narrative leans on child protection and bad actors, yet the statutory language does not distinguish heavily between synthetic gummies at the corner store and age gated, lab tested beverages running through alcohol distribution. That lack of nuance hands federal and state enforcers a blunt instrument and invites uneven, complaint driven crackdowns that will reward incumbents with lawyers and compliance budgets. At the same time, it creates pressure on governors, attorneys general, state legislators and cannabis regulators to decide whether they want to absorb any part of this market into marijuana frameworks or let it die and accept that consumers will chase THC into whatever channel remains. Executives who treated hemp as a side bet now have to underwrite it as core federal drug policy risk tied to leadership level trades rather than agriculture committee debates.

🌿 Trump Signs Hemp THC Ban And Starts The Countdown To Confusion

Donald Trump signed the shutdown bill and locked in the federal hemp THC ban, opening a twelve month window that will function more like a bruising negotiation over what, if anything, survives than a true grace period. The law keeps the 0.4 milligram cap and plant-only standard, so five and ten milligram drinks, THCA flower, and most conversion chemistry are still on the chopping block unless Congress rewrites its own work. Over the next year, access will not disappear overnight; products will thin out as retailers lose card processing, insurers balk, and house counsel finally reads the statute, which means consumers learn about the ban one awkward checkout conversation at a time. Members of Congress will not be the ones explaining why a favorite drink vanished or why a CBD line suddenly changed formulas, that job falls to store clerks, bartenders, and manufacturers who now have to translate D.C. drug policy into plain English. Executives who treat this year as a live negotiation instead of a slow funeral and arm their front-line staff with clear explanations and next-step options will be the ones who still have a customer base when the countdown ends. (Marijuana Moment)

🏛️ Minnesota Lawmakers Fight Federal Hemp Ban Threatening $200M State-Regulated Market

Minnesota senators Scott Dibble and Lindsey Port, who wrote the state’s 2022 hemp THC law and the follow-on cannabis bill, are pressing their congressional delegation to kill the federal hemp ban that would erase Minnesota’s roughly $200 million, 5,000-retailer regulated market. They describe the shutdown language as reckless interference with a state’s right to run its own markets and accuse McConnell of letting entrenched competitors turn Congress into a blunt tool against Minnesota’s framework. Minnesota is the clearest collision so far between a state that built real licensing, enforcement, and tax infrastructure for hemp THC and a federal regime that now brands those same products illegal regardless of compliance or the one-year phaseout. The state has no preemption workaround, so its tools are politics and litigation: pressure the delegation, explore constitutional angles, and stall implementation while cases move. Anyone watching from another regulated hemp state should read Minnesota’s posture as a preview of how quickly careful state design work can get bulldozed when federal drug politics and alcohol lobbying priorities move to the front of the line. (Minnesota Senate DFL)

🌾 Shutdown Hemp Deal Puts Farm States At War With Their Own Leaders

South Dakota’s hemp beverage and CBD retailers are staring at extinction under the 0.4 milligram per container cap at the same moment their senior senator, John Thune, is carrying the shutdown deal that locks it in. The crackdown language comes from Mitch McConnell, architect of the 2018 Farm Bill hemp boom, whose Kentucky farmers helped build the modern hemp economy that would now lose most of its cannabinoid product line. That alignment puts two powerful Republicans from farm-heavy states on the same side of a federal fix their own in-state businesses describe as a kill shot for beverages and higher potency CBD products. It also tells you hemp policy now lives in leadership offices and late-night negotiations, not agriculture committees and methodical hearings about farming and product safety. Any jurisdiction that let hemp beverages grow inside beer and grocery channels should treat the Thune and McConnell partnership as a bright red warning flare about whose interests really get protected when shutdown math collides with THC politics. (South Dakota Searchlight)

🌊 Rhode Island Hemp Caught Between Organic Growers And Shutdown Ban

Rhode Island Current centers Lovewell Farms, the state’s only outdoor hemp farm, whose USDA organic crops test up to 1 milligram THC under state rules and would become unsellable under the new 0.4 milligram federal cap, even though the company does not make intoxicating products. Regulators only opened the door to low-dose hemp drinks in August 2024 through the now-defunct Office of Cannabis Regulation, and the new Cannabis Office has been writing dosage, packaging, and licensing standards while the shutdown bill suddenly threatens to erase the entire category. Liquor Operators Collaborative head Nicholas Fede warns that if hemp beverages fall under federal Schedule 1 rules instead of a clarified hemp framework, Rhode Island retailers lose credit card processing, face separate bank accounts, and see a clean distribution system tossed into chaos overnight. Attorney General Peter Neronha backed the multistate AG letter pushing Congress to close the “THC loophole,” and Reed and Whitehouse voted to table Rand Paul’s amendment, which means Rhode Island’s own political leadership is now aligned with a federal move that undercuts a regulated, age-gated market they just started building. Executives should read Rhode Island as a case study in how quickly a state that tried to do hemp drinks “the right way” through liquor stores and testing can find its entire plan invalidated by one federal definition change while regulators are midstream on their rule set. (Rhode Island Current)

🌿 Ohio Floats Selective Defiance Of Federal Hemp Ban

Ohio officials are openly weighing whether to comply with Congress’s hemp crackdown even as small brands warn the 0.4 milligram cap would erase their businesses and strand thousands of daily customers. Governor Mike DeWine already tried to slam the door through an executive order, but a judge froze that move and left retailers, law enforcement, and consumers operating in a legal fog. Now House Speaker Matt Huffman is acknowledging THC is not leaving Ohio and has started talking about handling it more like alcohol, with clear channels and age checks instead of a patchwork of gas station shelves and court fights. Legal scholars like Jonathan Adler argue Washington has nowhere near the boots or budget to chase down every Ohio retailer, which gives state leaders space to play with selective enforcement or slow-walked compliance. If Ohio keeps low-dose hemp drinks flowing while it rewrites rules, that becomes the first real blueprint for state-level resistance to a federal hemp ban and governors in every purple state will take notes. (News 5 Cleveland)

🌿 Democratic Senator Opens Door to Hemp Regulatory Fix During One-Year Ban Window

Senator Chris Van Hollen voted for the hemp ban but immediately floated a plan to use the one-year implementation window to design science-based rules that keep access to products like CBD while shutting down the worst actors. The House Rules Committee blocked every amendment to the shutdown bill, including Thomas Massie’s move to strip the hemp language, and Rep. Morgan Griffith admitted he dislikes the crackdown yet feels boxed in by pressure to reopen the government. Van Hollen’s explanation matters because he framed his vote as a temporary tool to close Maryland’s enforcement gap, then turned around and invited hemp and CBD interests to help build a replacement framework before the year is up. That invitation creates a real organizing target for companies that already run age checks, lab testing, and potency caps and want to distinguish themselves from gas station chemistry experiments. If industry players treat this year as a lobbying sprint instead of a mourning period, they at least give themselves a chance at a real federal framework that keeps some of the hemp economy alive. (Marijuana Moment)

🚓 Scutari Bill Targets Unlicensed Shops And Rewrites Power Map For NJ CRC

New Jersey Senate President Nick Scutari’s bill orders State Police to build a formal enforcement program against unlicensed cannabis shops and arms them with powers to shut businesses, seize product, and push cases into criminal court. Buried in the same package are changes that loosen conflict rules so officials and their families can work for or invest in cannabis companies with ethics signoff, and that let Scutari allies sit on the Cannabis Regulatory Commission while holding local office and raising money. The bill also strips the CRC chair of direct supervisory authority, hands chair selection to a commissioner majority, and softens rules around private meetings between commissioners, staff, and applicants. On the municipal front it lets medical dispensaries flip to adult-use without new local approvals and insulates them from certain town caps if their record is clean, which is a nice advantage if you are already on the inside. The whole thing comes off as a governance reset dressed up as an enforcement tweak, tightening the political grip on New Jersey’s cannabis market in a way regulators and operators in other states will recognize immediately. (Heady NJ)

🗳️ Florida Procedural Support Masks 2026 Ballot Execution Risk

Trump’s pollster found that 89%of likely Florida voters say they should decide marijuana legalization themselves, with eye-popping support across Democrats, independents, and Republicans, yet the 2026 Smart & Safe initiative sits in administrative quicksand while officials argue over petition formatting and try to toss 200,000 signatures. Governor Ron DeSantis already bragged that the measure is in big trouble at the state Supreme Court after he helped kill the 2024 version, and his track record on these calls has been uncomfortably accurate for reform advocates. The gap between overwhelming public support and a state machinery that keeps the question off the ballot creates a very specific risk that sophisticated operators need to factor into Florida market plans. In this environment, signature counts and top-line polling numbers become soft comfort because the real choke point is whether petitions survive technical challenges long enough to reach voters. Anyone betting heavily on Florida needs to think less about likely vote shares and more about whether opponents can keep moving the procedural goalposts until the clock runs out. (Marijuana Moment)

💊 Medical Cannabis Keeps Eating Into Opioid Prescriptions

University of Georgia researchers just dropped two more studies showing what patients and pain specialists have been saying quietly for years: when states open medical cannabis channels, opioid prescriptions fall. One JAMA Health Forum paper tracks commercially insured cancer patients and finds dispensary openings cut the share of patients on opioids, shortened the average days’ supply, and reduced prescriptions per patient, while a companion study in the American Journal of Health Economics finds medical cannabis laws drive a roughly 16 percent drop in opioid prescribing across a 15 to 20 million person dataset. The pattern holds across age, sex, and race, with even bigger reductions for cancer patients and non-cancer Black patients, and it lines up with prior work that found chronic pain patients swap out opioids for cannabis in large numbers when the option becomes legal. Policymakers who still talk about cannabis as a “gateway” drug are now staring at peer-reviewed data that points the other way, and payers will eventually have to decide whether they keep footing the bill for higher-risk pain regimens in states that refuse to modernize their laws. The bigger strategic question is how long federal law can pretend this substitution effect is a side note when actuaries, hospital systems, and state budget writers start baking it into their assumptions about overdose, disability, and long-term care costs. (Ganjapreneur)

🚗 Cannabis Delivery And Insurance Fight Land On Rideshare Lobbying Agenda

In Alberta, ride-for-hire companies are leaning hard on regulators over two issues that matter for cannabis and for anyone moving product or people on wheels: delivery rules and insurance costs. Uber has been meeting officials about cannabis delivery, trying to secure clear pathways for drivers to move regulated product without tripping over criminal law, provincial cannabis rules, or municipal bylaws. Lyft is pushing from a different angle, arguing its drivers should not need full commercial licenses, which would keep costs down but raises obvious questions about liability if someone is moving cannabis or passengers under a lighter regulatory touch. Taxi operators are asking to be treated more like rideshare platforms, especially around insurance and licensing breaks that tech companies have normalized. What matters here is that cannabis delivery, auto insurance, and gig-worker status now live in the same lobbying conversations, which means the next round of cannabis logistics fights will not stay trapped in siloed cannabis hearings. (Investigative Journalism Foundation)

📊 Medical Cannabis Becomes A Mainstream Therapy In Israel, Then Hits HMO Gatekeeping

Israel’s medical cannabis program grew more than 4,400 percent from 3,097 active licenses in 2011 to a peak of 140,483 in January 2024, driven by expanded indications, pharmacy access, and a shift of prescribing authority from a small government unit to trained physicians and HMOs. Chronic non-cancer pain now accounts for about 63 percent of licenses and PTSD has nearly doubled to 17 percent, with most patients approved for 40–60 grams per month and more than 94 percent of use still in dried flower form. A 2019 move to per-product pharmacy pricing and a 2024 HMO-led prescribing reform nudged the market into a more medical model but also produced a 7.5 percent drop in active licenses and new data gaps around indications, which the authors link to stricter gatekeeping and post-investigation cleanup of irregular licenses. At its peak the program’s annual value sat somewhere between 252 and 684 million dollars, which means any change to prescribing rules, prices, or reporting standards now carries real fiscal weight for patients, providers, and the state. For regulators and executives elsewhere, Israel’s trajectory is a live case study in how quickly medical cannabis can scale once doctors buy in, and how fast it can flatten when prescription power shifts to cost-conscious health plans without matching transparency. At some point federal law has to catch up, because actuaries, hospital systems, and state budget writers are already baking this substitution effect into their expectations for overdoses, disability, and long-term care. (Journal of Cannabis Research)